

| Location | Correction |
|------------------------|---|
| Chapter 4.3.1, page 38 | <p>The reference indicated as ref ²⁹ (in superscript) was missing in the list of used literature. The correct reference is: European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Determination of minimum inhibitory – concentrations (MICs) of antibacterial agents by broth dilution. <i>Clin. Microbiol. Infect.</i> 2003, 9 (8), 1–7. DOI: 10.1046/j.1469-0691.2003.00790.x</p> |
| Chapter 4.3.2, page 38 | <p>The reference indicated as ref ²⁸ (in superscript) was missing in the list of used literature. The correct reference is: Franzblau, S. G.; Witzig, R. S.; McLaughlin, J. C.; Torres, P.; Madico, G.; Hernandez, A.; Degnan, M. T.; Cook, M. B.; Quenzer, V. K.; Ferguson, R. M.; Gilman, R. H. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. <i>J. Clin. Microbiol.</i> 1998, 36 (2), 362–366. DOI: 10.1128/JCM.36.2.362-366.1998.</p> <p>Ref [52] was missing in the text.</p> |
| Chapter 4.3.3, page 39 | <p>Ref [52] was missing in the text.</p> |
| Chapter 4.3.4, page 40 | <p>The references indicated as ref ³⁰ (in superscript) was missing in the list of used literature. The correct references are: Arendrup, M. C.; Cuenca-Estrella, M.; Lass-Flörl, C.; Hope, W. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). <i>Clin. Microbiol. Infect.</i> 2012, 18 (7), E246–E247. DOI: 10.1111/j.1469-0691.2012.03880.x Arendrup, M. C.; Mouton, J. W.; Lagrou, K.; Hamal, P.; Guinea, J.; Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST) Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. <i>Clin. Microbiol. Infect.</i> 2017, 72 (12). DOI: 10.1111/j.1469-0691.2008.02086.x</p> <p>Ref [52] was missing in the text.</p> |

| | |
|-------------|--|
| Chapter 4.3 | <p>In this chapter, I regret that I omitted to acknowledge the people who performed the biological testing.</p> <p>Antibacterial + antifungal testing performed by:</p> <ul style="list-style-type: none"> • <u>Group of microbiology and immunology, Department of Biological and Medical Sciences</u>, RNDr. Klára Konečná, Ph.D., Ida Dufková, Ing. Jana Vacková <p>Antimycobacterial testing – <i>M. tuberculosis</i> H37Ra, <i>M. avium</i>, <i>M. kansasii</i>, <i>M. smegmatis</i>, <i>M. aurum</i> performed by:</p> <ul style="list-style-type: none"> • <u>Group of microbiology and immunology, Department of Biological and Medical Sciences</u>, PharmDr. Ondřej Jandourek, Ph.D. <p>Antimycobacterial testing – <i>M. tuberculosis</i> H37Rv, MDR mycobacterial strains performed by:</p> <ul style="list-style-type: none"> • Department of Clinical Microbiology, University Hospital Hradec Králové, Hradec Králové, Czech Republic, MUDr. Pavla Paterová, Ph.D. |
|-------------|--|

- [52] D.E. Nawrot, G. Bouz, O. Jandourek, K. Konečná, P. Paterová, P. Bárta, M. Novák, R. Kučera, J. Zemanová, M. Forbak, J. Korduláková, O. Pavliš, P. Kubíčková, M. Doležal, J. Zitko, Antimycobacterial pyridine carboxamides: From design to *in vivo* activity, Eur. J. Med. Chem. 258 (2023) 115617. <https://doi.org/10.1016/j.ejmech.2023.115617>.